About 10 weeks after it was approved, the Wegovy pill is now estimated to be part of the daily regimen of about 400,000 Americans. And the field of weight-loss treatment is on the verge of even more ...

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established ...

Analysts are intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they say it's too early assess its market potential against orforglipron.

The global weight-loss drug market is entering a new phase, driven by the arrival of oral options, looming generic rivals and falling U.S. prices for blockbuster treatments from Eli Lilly and Novo ...

March 6 (Reuters) - The global weight-loss drug market is entering a new phase, driven by the arrival of oral options, looming generic rivals and falling U.S. prices for blockbuster treatments from ...

The FDA granted Priority Review to the BLA for Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic for the treatment of hematological malignancies including acute myeloid leukemia, acute ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The era of GLP-1 weight loss ...

Pharmaceutical giant Eli Lilly faces a pivotal regulatory milestone in March 2026, with the U.S. Food and Drug Administration (FDA) poised to rule on Orforglipron. This oral GLP-1 weight-loss drug ...

NEW YORK CITY — Eli Lilly CFO Lucas ‌Montarce said on Monday it is preparing to launch its new ⁠oral obesity drug, orforglipron, in the United States ⁠as early as the second quarter of this ‌year, ...

Originally developed for Type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the weight-loss medication market. And in recent years, their popularity has soared due to ...